Cargando…

Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model

PURPOSE: Vitamin B(12) (cyanocobalamin, Cbl) is accumulated by rapidly replicating prokaryotic and eukaryotic cells. We investigated the potential of a Tc-99m labelled Cbl derivative ([(99m)Tc]PAMA(4)-Cbl) for targeting infections caused by Escherichia coli and Staphylococcus aureus. In vitro bindin...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldoni, Daniela, Waibel, Robert, Bläuenstein, Peter, Galli, Filippo, Iodice, Violetta, Signore, Alberto, Schibli, Roger, Trampuz, Andrej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641156/
https://www.ncbi.nlm.nih.gov/pubmed/25860122
http://dx.doi.org/10.1007/s11307-015-0832-x
_version_ 1782400148628832256
author Baldoni, Daniela
Waibel, Robert
Bläuenstein, Peter
Galli, Filippo
Iodice, Violetta
Signore, Alberto
Schibli, Roger
Trampuz, Andrej
author_facet Baldoni, Daniela
Waibel, Robert
Bläuenstein, Peter
Galli, Filippo
Iodice, Violetta
Signore, Alberto
Schibli, Roger
Trampuz, Andrej
author_sort Baldoni, Daniela
collection PubMed
description PURPOSE: Vitamin B(12) (cyanocobalamin, Cbl) is accumulated by rapidly replicating prokaryotic and eukaryotic cells. We investigated the potential of a Tc-99m labelled Cbl derivative ([(99m)Tc]PAMA(4)-Cbl) for targeting infections caused by Escherichia coli and Staphylococcus aureus. In vitro binding assays were followed by biodistribution studies in a mouse model of foreign body infection. PROCEDURES: E. coli (ATCC 25922) and S. aureus (ATCC 43335) were used as test strains. [(57)Co]Cbl, [(67)Ga]citrate and [(99m)Tc]DTPA served as reference compounds. The in vitro competitive binding of [(57)Co]Cbl or [(99m)Tc]PAMA(4)-Cbl, and unlabeled Cbl, to viable or killed bacteria, was evaluated at 37 and 4 °C. A cage mouse model of infection was used for biodistribution of intravenous [(57)Co]Cbl and [(99m)Tc]PAMA(4)-Cbl in cage and dissected tissues of infected and non-infected mice. RESULTS: Maximum binding (mean ± SD) of [(57)Co]Cbl to viable E. coli was 81.7 ± 2.6 % and to S. aureus 34.0 ± 6.7 %, at 37 °C; no binding occurred to heat-killed bacteria. Binding to both test strains was displaced by 100- to 1000-fold excess of unlabeled Cbl. The in vitro binding of [(99m)Tc]PAMA(4)-Cbl was 100-fold and 3-fold lower than the one of [(57)Co]Cbl for E. coli and S. aureus, respectively. In vivo, [(99m)Tc]PAMA(4)-Cbl showed peak percentage of injected dose (% ID) values between 1.33 and 2.3, at 30 min post-injection (p.i.). Significantly higher retention occurred in cage fluids infected with S. aureus at 4 h and with E. coli at 8 h p.i. than in non-infected animals. Accumulation into infected cages was also higher than the one of [(99m)Tc]DTPA, which showed similar biodistribution in infected and sterile mice. [(57)Co]Cbl gradually accumulated in cages with peaks % ID between 3.58 and 4.83 % achieved from 24 to 48 h. Discrimination for infection occurred only in E. coli-infected mice, at 72 h p.i. [(67)Ga]citrate, which showed a gradual accumulation into cage fluids during 12 h, was discriminative for infection from 48 to 72 h p.i. (P < 0.05). CONCLUSION: Cbl displayed rapid and specific in vitro binding to test strains. [(99m)Tc]PAMA(4)-Cbl was rapidly cleared from most tissues and discriminated between sterile and infected cages, being a promising candidate for imaging infections in humans.
format Online
Article
Text
id pubmed-4641156
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-46411562015-11-13 Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model Baldoni, Daniela Waibel, Robert Bläuenstein, Peter Galli, Filippo Iodice, Violetta Signore, Alberto Schibli, Roger Trampuz, Andrej Mol Imaging Biol Research Article PURPOSE: Vitamin B(12) (cyanocobalamin, Cbl) is accumulated by rapidly replicating prokaryotic and eukaryotic cells. We investigated the potential of a Tc-99m labelled Cbl derivative ([(99m)Tc]PAMA(4)-Cbl) for targeting infections caused by Escherichia coli and Staphylococcus aureus. In vitro binding assays were followed by biodistribution studies in a mouse model of foreign body infection. PROCEDURES: E. coli (ATCC 25922) and S. aureus (ATCC 43335) were used as test strains. [(57)Co]Cbl, [(67)Ga]citrate and [(99m)Tc]DTPA served as reference compounds. The in vitro competitive binding of [(57)Co]Cbl or [(99m)Tc]PAMA(4)-Cbl, and unlabeled Cbl, to viable or killed bacteria, was evaluated at 37 and 4 °C. A cage mouse model of infection was used for biodistribution of intravenous [(57)Co]Cbl and [(99m)Tc]PAMA(4)-Cbl in cage and dissected tissues of infected and non-infected mice. RESULTS: Maximum binding (mean ± SD) of [(57)Co]Cbl to viable E. coli was 81.7 ± 2.6 % and to S. aureus 34.0 ± 6.7 %, at 37 °C; no binding occurred to heat-killed bacteria. Binding to both test strains was displaced by 100- to 1000-fold excess of unlabeled Cbl. The in vitro binding of [(99m)Tc]PAMA(4)-Cbl was 100-fold and 3-fold lower than the one of [(57)Co]Cbl for E. coli and S. aureus, respectively. In vivo, [(99m)Tc]PAMA(4)-Cbl showed peak percentage of injected dose (% ID) values between 1.33 and 2.3, at 30 min post-injection (p.i.). Significantly higher retention occurred in cage fluids infected with S. aureus at 4 h and with E. coli at 8 h p.i. than in non-infected animals. Accumulation into infected cages was also higher than the one of [(99m)Tc]DTPA, which showed similar biodistribution in infected and sterile mice. [(57)Co]Cbl gradually accumulated in cages with peaks % ID between 3.58 and 4.83 % achieved from 24 to 48 h. Discrimination for infection occurred only in E. coli-infected mice, at 72 h p.i. [(67)Ga]citrate, which showed a gradual accumulation into cage fluids during 12 h, was discriminative for infection from 48 to 72 h p.i. (P < 0.05). CONCLUSION: Cbl displayed rapid and specific in vitro binding to test strains. [(99m)Tc]PAMA(4)-Cbl was rapidly cleared from most tissues and discriminated between sterile and infected cages, being a promising candidate for imaging infections in humans. Springer US 2015-04-10 2015 /pmc/articles/PMC4641156/ /pubmed/25860122 http://dx.doi.org/10.1007/s11307-015-0832-x Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
Baldoni, Daniela
Waibel, Robert
Bläuenstein, Peter
Galli, Filippo
Iodice, Violetta
Signore, Alberto
Schibli, Roger
Trampuz, Andrej
Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model
title Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model
title_full Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model
title_fullStr Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model
title_full_unstemmed Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model
title_short Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model
title_sort evaluation of a novel tc-99m labelled vitamin b(12) derivative for targeting escherichia coli and staphylococcus aureus in vitro and in an experimental foreign-body infection model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641156/
https://www.ncbi.nlm.nih.gov/pubmed/25860122
http://dx.doi.org/10.1007/s11307-015-0832-x
work_keys_str_mv AT baldonidaniela evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel
AT waibelrobert evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel
AT blauensteinpeter evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel
AT gallifilippo evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel
AT iodicevioletta evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel
AT signorealberto evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel
AT schibliroger evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel
AT trampuzandrej evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel